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Chemotherapy Induced Pathologic Complete Response in
Malignant Pleural Mesothelioma
A Review and Case Report
Cecilia Bech, MD, and Jens Benn Sørensen, MD, DMSc, MPA
Introduction: Malignant pleural mesothelioma is a rare aggressive
disease with a poor prognosis and usually modest responses to
chemotherapy.
Complete responses (CRs) to chemotherapy are rare. Evalu-
ation is usually based on radiology, and CR is therefore clinical CR
(cCR) and whether this indicates absence of viable tumor cells is
unknown. We have observed two cases of CR which at subsequent
surgery were histologically verified, thus being pathologic CRs
(pCRs). pCR after chemotherapy is thus possible but rare, and we
here present the cases from our institution together with a review on
the literature available on the subject.
Methods: A literature search using relevant keywords was per-
formed in PubMed and MedLine.
Results: A larger number of reports on cCR but only five reports on
pCR were identified. All published cases of pCR, 16 patients in five
trials, are presented and discussed, and larger trials reporting cCR
are mentioned. pCR did not in all cases correspond to cCR. The
cases having pCR identified all had the epithelial or unknown
subtype, and all had early-stage disease before treatment.
Conclusion: pCR is possible but rare, and a pCR does not always
require a cCR. So far reported cases of pCR have all had the
epithelial or unknown subtype and pretreatment stages have been
low. The cases in our institution also had epithelial subtype but had
stage III disease ,and it thus seems possible to obtain a pCR despite
a larger tumor burden.
Key Words: Malignant pleural mesothelioma, Complete response,
Clinically complete response, Pathologically complete response,
CR, cCR, pCR.
(J Thorac Oncol. 2010;5: 735–740)
Malignant pleural mesothelioma (MPM) is a rare dis-ease with a poor prognosis. Patients often present in
advanced stage, and this, together with the fact that this
neoplasm often has a diffuse spreading growth, means that
the majority of patients are inoperable at the time of
diagnosis. Palliative chemotherapy is the only treatment
option in these cases. A small proportion of patients with
early-stage disease may be potential candidates for sur-
gery. There is no universally accepted treatment strategy in
early-stage disease, but recently published guidelines sug-
gest surgery combined with chemotherapy and radiation
(trimodal treatment).1 Patients who are potentially candi-
dates for such curatively intended treatment should be
carefully selected and are usually treated with induction
chemotherapy followed by extrapleural pneumonectomy
(EPP) and subsequent adjuvant hemithoracic radiation.
This may be the most promising way of achieving cure or
at least long-term survival in selected patients though it is
not based on randomized trials that are inherently difficult
to conduct among these relatively rare cases.
Chemotherapy is thus usually part of the treatment
strategy in MPM of all stages, either alone in a palliative
setting or as part of the trimodality approach. Response
rates to combination chemotherapy regimens are not im-
pressive, usually ranging from 13 to 41%.2–5 Cisplatin-
based combination regimens have proved more active than
single-agent cisplatin alone,4,5 and it is generally accepted
based on these trials that the standard treatment is a
platinum combined with another active drug, often pem-
etrexed.5 Several other agents, such as raltitrexed,4 gem-
citabine,6 and vinorelbine,3 have also been efficacious in
combination with a platinum and may possibly be as
efficient as the cisplatin/pemetrexed combination, but no
chemotherapy regimen has so far been evaluated against
another combination regimen in a randomized trial.
Even though response rates to chemotherapy are usu-
ally quite modest, it seems that a much more impressive
result may be achieved in few cases. We have in our institu-
tion observed one case of pathologic confirmed complete
response (pCR), i.e., without viable tumor cells in the spec-
imen and one case of “near pCR” to chemotherapy. This is
thus possible, however rare, and we accordingly searched the
literature about this topic. The result of this review on the
occurrence of pCR after chemotherapy alone verified by
histopathologic examination is presented together with a
description of the two cases from our own institution.
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METHODS
A clinical complete response (cCR) is radiologically
defined by disappearance of all signs of disease evaluated
clinically and radiologically, mainly by use of computed
tomography (CT) scan, positron emission tomography
(PET)/CT scan, or magnetic resonance (MR) scan. A pCR is
defined by verification of absence of malignant cells by
histopathologic examination, either of the whole pleura spec-
imen removed by surgery such as EPP or pleurectomy or by
use of biopsies obtained by thoracoscopy or thoracotomy.
An extensive literature search was performed in Sep-
tember 2009, using PubMed and Medline together with
references found through the articles discovered there. Ab-
stracts were reviewed and when found relevant, full articles
were retrieved to illuminate how frequent complete responses
(CRs) to chemotherapy are when based on radiology only
(cCR) and to discuss published cases of pCR. Key words
used were “malignant pleural mesothelioma” in combination
with “pathologic complete response,” “complete response,”
“CR,” “pathologic complete remission,” “complete remis-
sion,” “histologic complete response,” and with and without
combination with “chemotherapy,” “cisplatin,” “carbopla-
tin,” “pemetrexed,” and “vinorelbine.” The full article was
retrieved in case CRs were mentioned, to further examine
whether these CRs were histologically verified. Also 10 of
the most recent and large studies of the effect of chemother-
apy in malignant mesothelioma were reviewed to identify the
number of CRs described in these studies and determine
whether any of these were histologically confirmed. A search
using key words “malignant pleural mesothelioma,” “EPP,”
“extrapleural pneumonectomy,” and “response” was also per-
formed, and the most recent larger studies with EPP were
reviewed to identify cases of pCR. Tables were made over all
cases of pCR identified (Tables 2 and 3) and to get an
overview of the rareness of cCR a table over a selection of
publications reporting this was made (Table 1). Because
publications reporting this were many throughout the years,
we chose to only include publications of phase III trials,
published within the last 10 years, with CT used for evalua-
tion, and where the chemotherapy was either cisplain versus
cisplatin/pemetrexed or cisplatin versus cisplatin/raltitrexed.
RESULTS
Case Presentations
The two cases described here were part of a study in our
department, in Table 3 referred to as “current study.” The
study consisted of 56 patients with epithelial MPM, receiving
three cycles of induction chemotherapy followed by EPP and
thoracic irradiation, 50 Gy in 30 fractions, 5 fractions per
week. Among these 56 patients pCR was achieved in two
cases.
Case 1
A 59-year-old previously healthy woman was diag-
nosed with MPM. She had no known exposition to asbes-
tos but developed coughing, dyspnoea, and recurrent pleu-
ral effusion on chest x-ray. Thoracoscopy with biopsies
confirmed the diagnosis of MPM of the epithelial subtype.
A PET/CT scan revealed enlarged lymph nodes retroster-
nally and two foci of structurally pathologic pleural thick-
ening on the left side. All these abnormalities were meta-
bolically active with fludeoxyglucose uptake. However, at
biopsy no malignant cells could be found in the glands, and
the patient had tumor, node, metastasis (TNM) stage
T3N0M0 and thus International Mesothelioma Interest
Group (IMIG) stage III. The patient received induction
chemotherapy with three courses of cisplatin, 75 mg/m2
and pemetrexed, 500 mg/m2, every 3 weeks. A partial
response was obtained on a subsequent new PET/CT scan,
pulmonary function test allowed left side pneumonectomy,
and she was referred for surgery and postoperative radio-
therapy. No macroscopic tumor tissue could be localized
during surgery, and the initially planned EPP was con-
verted to a pleurectomy. The histopathologic examination
of the pleura specimen revealed no malignant cells, despite
thorough examination on 100 histologic slides from vari-
ous positions of the resected pleura. The surgical patho-
logic TNM status was thus T0N0M0, and the patient was
considered to have a pCR. The patient did not receive
postoperative radiotherapy or any other further treatment
but was followed with clinical controls and PET/CT scans.
She is now, 14 months later, still alive without signs of
relapse clinically or radiologically.
Case 2
A 62-year-old previously healthy man was diagnosed
with right-sided MPM of the epithelial subtype. He had
been asbestos exposed, developed dyspnoea, and chest
x-ray revealed a pleural effusion. Thoracoscopy with bi-
opsies confirmed the diagnosis. CT scan revealed thicken-
ing of a major part of the right pleura and of the right
pericardium wall. TNM classification was T3N2M0 and
IMIG stage thus stage III. Treatment with four courses of
carboplatin and pemetrexed was initiated after which the
pleural effusion declined, whereas no response on the
TABLE 1. Complete Responses to Chemotherapy by Radiological Evaluation (cCR), Selected Trials
Authors Year Treatment No. of Patients
Histology, n (%)
CR, n (%)Epithelial Sarcomatous Biphasic
van Meerbeeck et al.4 2005 CDDP  raltitrexed 213 169 (79) 13 (6) 48 (23) 2 (1)
Vogelzang et al.5 2003 CDDP  pemetrexed 448 306 (68) 43 (10) 73 (16) 0 (0)
Total 661 2 (0.3)
CDDP, cisplatin.
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pleural changes could be seen on CT scan after four
treatment courses. The pulmonary function tests allowed
for right side pneumonectomy, and a preoperative PET/CT
scan confirmed the same pleural changes as above without
signs of spreading to the thoracic wall, pericardium, dia-
phragm, mediastinum, or distant. Mediastinoscopy with
lymph node biopsies from station 4R, 4L, and 2R were
negative and a right-sided EPP was performed. The sur-
gery was without complications, and the whole right lung
and pleura specimen was taken out and examined. The
resection margins were all free without signs of malig-
nancy, and pathologic examination of the resected lung
and pleura specimen showed primarily benign changes
with inflammation and necrosis. Only one microscopic
focus of few malignant cells of mesothelial origin was
discovered. Thus, the patient had an impressive response
to the chemotherapy, very close to a pCR. The operation
was a microscopically complete R0 resection. The patient
also received postoperative adjuvant radiotherapy with 50
Gy in 30 fractions, 5 fractions per week, with IMRT
technique to the right thoracic wall, right diaphragm, and
mediastinum. The patient was followed by clinical and
radiologic follow-up visits, and after 15 months he re-
lapsed. He then received reinduction treatment with car-
boplatin and pemetrexed, six courses after which pleural
effusion again reoccurred, and he received two courses of
CCG (carboplatin  liposomized doxorubicin  gemcit-
abine) treatment. This did not induce any response and the
disease progressed further and the patient died, 39 months
from initial diagnosis and 29 months from the end of the
trimodality treatment.
Literature Review
Clinical CR (Table 1)
Only two large phase III studies published within the
last 10 years, and where chemotherapy was platinum
based, were found, as shown in Table 1. One, the random-
ized trial by Vogelzang et al.5 using cisplatin and pem-
etrexed revealed an overall response rate of 41.3% which
were all partial responses and no CRs. A handful of other
studies reported cCR rates varying from 1 to 4%, but as
mentioned earlier most of these studies were old, not phase
III, had very small patient samples and very different
chemotherapy regimens had been used. These studies were
thus excluded. The only other large phase III study pub-
lished within the last 10 years, using platinum based
chemotherapy was published by van Meerbeeck et al.,4 and
here cCR was described in only two patients (1%), which
is shown in Table 1.
CR Verified by Histology, i.e., pCR
Cases of pathologically confirmed CRs without via-
ble tumor cells (pCR) were rarely reported and results
from the literature review are given in Tables 2 and 3.
Table 2 shows pCRs verified by histologic examination of
multiple biopsies taken by thoracoscopy or thoracotomy. A
total of nine pCRs were identified in two separate trials7,8
among a total of 111 patients included. The pCR rate
ranged from 5 to 9%. The percentages of epithelial subtype
were 80 and 86 in the whole materials. It was not possi-
ble to identify the subtypes of the patients having pCR in
TABLE 2. Histopathologically Verified Complete Responses (pCR), Evaluated by Biopsies from Selected Sites
Authors Year Treatment No of Patients
Histology, n (%)
Methods CR, n (%)Epithelial Sarcomatous Biphasic
Boutin et al.8 1994 Intrapleural gamma-
interferon
89 71 (80) 0 (0) 18 (20) Thoracoscopy (n  11) or thoracotomy
(n  6), with biopsies
8 (9)
Astoul et al.7 1998 Intrapleural IL-2 22 19 (86) 1 (5) 2 (9) Thoracoscopy with biopsies 1 (5)
Total 111 9 (8)
CR, complete response; IL-2, interleukin-2.
TABLE 3. Histopathologic Complete Responses (pCR) to Chemotherapy, Evaluated by Examination of Resected Whole Pleura







n (%)Epithelial Sarcomatous Biphasic
Astoul et al.10 1993 Intrapleural IL-2 15 11 (73) 1 (7) 3 (20) EPP 1 (7)
Shin et al.11 1995 Cyclophosphamide 23 14 (61) 4 (17) 1 (4) “Surgical resection,” NOS 1 (4)
 Doxorubicin
 Cisplatin
Krug et al.12 2009 Cisplatin  Pemetrexed 77 62 (81) 1 (1) 2 (3) EPP 3 (4)
Current studya 2009 Pemetrexed  CDDP/CBDCA 56 56 (100) 0 0 EPP/pleurectomy 2 (4)
Total 171 7 (4)
a Fifty-six patients with epithelial malignant pleural mesothelioma, receiving three cycles of induction chemotherapy followed by extrapleural pneumonectomy and thoracic
irradiation, 50 Gy in 30 fractions, 5 F/W.
IL-2, interleukin-2; EPP, extrapleural pneumonectomy; CDDP, cisplatin; CBDCA, carboplatin; NOS, not otherwise specified.
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one of the studies,8 whereas in the other study, all patients
having a pCR had the epithelial subtype.7
Boutin et al.8 reported on the effects of intrapleural
treatment with gamma-interferon in 89 patients with
MPM. Patients were mainly early-stage disease (stage I or
II, Butchart classification9), and they received through
catheter gamma-interferon intrapleurally twice weekly for
8 weeks. Evaluation was done 2 weeks after treatment, and
a thoracoscopy or thoracotomy with removal of multiple
biopsies was performed if CT scan demonstrated response
or stabilization. CR was defined as disappearance of mac-
roscopic and microscopic disease, i.e., pCR. Overall re-
sponse rate was 19%, eight patients (9%) had a pCR of
which 7 had pretreatment stage I, and the last had stage II
disease, and the mean duration of pCR was 19 months.
Astoul et al.7 reported on a similar study in which 22
patients received continuous infusion of intrapleural interleu-
kin (IL)-2 for 5 days. Response was evaluated by World
Health Organization criteria on CT scan, and thoracoscopy
with multiple biopsies was performed in case of radiology
demonstrating response. CR was defined as the disappearance
of macroscopic and microscopic disease, i.e., pCR. This was
obtained for one patient (5%) who had initial stage 1A,
according to Butchart staging classification.9
As earlier mentioned, pCR were in these two reports
evaluated by histologic examination of biopsies from several
sites, taken by thoracoscopy or thoracotomy. This is prob-
lematic, as the complex and diffuse anatomy and growth
pattern of the pleura and of mesothelioma makes it uncertain
whether all viable tumor cells have disappeared, even if none
are to be found in the biopsies. Therefore, these cases are not
100% certain to be “true pCRs,” which would demand ex-
amination of every part of the pleura. However, we have
chosen to include these cases anyways, to further illustrate
the rareness of pCR in mesothelioma.
Induction chemotherapy before surgery has also been
occasionally reported to induce pCR, which followingly
has been verified by histologic examination of the whole
surgical specimen. As mentioned earlier, this must be the
most precise method of evaluating pCR and must be
regarded as the “golden standard,” and the pCRs described
here are the closest to “true pCR” as possible. We only
discovered three such reports with a total of five patients
with pCR defined by histologic examination of the surgical
specimen after surgery (Table 3). The three reports de-
scribed a total of 115 patients, which together with our
own trial of 56 patients gave a total of 171 patients. Thus,
a total of seven pCRs were identified in these four trials,
leading to a pCR rate of 4%. It was not possible to identify
the specific histologic subtype of the patients having pCR
in all the three published reports, but where information
was available the subtype was either epithelial or un-
known, whereas no cases of pCR in patients with the
sarcomatous or biphasic subtype have been specifically
described. The two patients with a pCR from our own
institution both had the epithelial subtype. Astoul et al.10
reported on a phase 1 study of intrapleural recombinant
IL-2. A total of 22 patients with malignant pleural effusion
were included among whom 15 patients had mesothelioma.
All patients received continuous infusion of IL-2 in-
trapleurally for 5 consecutive days. Patients were evalu-
ated before and 36 days after treatment start by CT scan.
Thoracoscopy with multiple biopsies was performed if a
response was seen, and two patients underwent pleuro-
pneumonectomy 6 weeks after treatment. One of these was
considered to have had a pCR to the IL-treatment because
histopathologic examination of the resected pleura re-
vealed no viable malignant cells. This patient had the
epithelial subtype and stage I disease at diagnosis (But-
chart classification9).
Shin et al.11 reported on a study including 23 patients
with unresectable MPM treated with a combination chemo-
therapy of cyclophosphamide, doxorubicin, and cisplatin.
Patients were evaluated by use of CT scan after three cycles
of treatment, and the overall response rate was 30%, all being
partial responses. One of these patients received three more
cycles of chemotherapy and subsequently had a pleurectomy.
The surgical specimen was histologically examined, and no
viable tumors could be found corresponding to a pCR. No
data on initial stage of disease or subtype for this patient were
available.
Many trials have been reported with induction che-
motherapy followed by surgery with postoperative histo-
logic examination of the removed specimen but only one
study by Krug et al.12 reported on cases of pCR. A total of
77 patients with MPM were enrolled, 64 received all four
planned cycles of cisplatin  pemetrexed and 54 patients
subsequently proceeded to EPP. The total radiologic re-
sponse rate after chemotherapy was 32.5%, and one patient
had a cCR (0.7%). Histopathologic examination of the
surgical specimens from 54 patients revealed that a total of
three patients (4%) had achieved a pCR. The 77 patients
included initially had mainly stage II and III disease
according to the IMIG classification system,13 and only six
patients had stage I disease. One of the patients having
pCR had pretreatment stage IA. This patient became long-
term survivor and was still alive after 25 months at the
time of study reporting. The two other patients with pCR
survived shorter time than the median of 16.8 months. The
pretreatment stages for these two patients were not avail-
able in the report. One had early progression whereas the
other died of respiratory failure.
DISCUSSION
Response rates to chemotherapy and other antineo-
plastic agents in the treatment of MPM are generally not
impressive. Most of the responses obtained are only par-
tial, and most of patients progress after relatively short
time. Little is known about what determines the length of
this period of stable disease, but it may be reasonable to
assume that large responses, e.g., cCRs are associated with
a better prognosis. Other factors for determining prognosis
have been explored, with the most important being perfor-
mance status, sex, histology, and white blood cell
count.14,15 Response assessment is usually done by clinical
and radiologic evaluation using CT scan, and a CR is thus
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defined as disappearance of all clinical findings and mea-
surable or evaluable lesions on CT scan, being a cCR.
However, many patients have chronic benign lesions in the
pleura, and persisting measurable lesions could theoreti-
cally be inactive without viable tumor cells and only
consisting of fibrosis, necrosis, asbestos plaques, or other
benign lesions. A cCR is thus not absolutely mandatory to
achieve a pCR.
Other radiologic modalities sometimes used in the
response evaluation are MR scan and PET/CT scan. The
question is whether these modalities are more accurate in
determining a response and in particular a CR. The benefit of
the MR scan is the high resolution, which to a higher extent
may permit differentiation of malignant from benign dis-
ease16 but without being proof of the histologic findings as it
is still a purely visual tool. PET/CT scan is increasingly used
in the diagnosis and treatment of mesothelioma, and it has
been superior compared with CT scan with respect to stag-
ing.17 The fact that it also measures the metabolic aspects
makes it reasonable to believe that it could turn out to be very
useful in response assessment.16 It remains unknown whether
a decrease in the PET signal is related to a pathologic
response, and it is also unknown whether the response
assessed by PET/CT scan is related to prognosis and survival,
which needs to be further investigated. If this is the case,
the value of PET/CT in the response evaluation to chemo-
therapy would increase as the PET response could possibly
be used as a marker for the pathologically proven response
such as pCR.
With the knowledge we have today, histologic ex-
amination is the only method available to examine for
viable tumor cells after chemotherapy or other systemic
treatment. Accordingly, histologic verification is needed if
the patient should be judged free of tumor (pCR). A pCR
could theoretically be present even though CT scan reveals
persistent tumor signs after treatment as these could be of
benign nature, and this point is also underscored by the
findings by the present case 2 presentation where the
patient had a clinical PR and a pCR. Dramatic responses to
treatment are relatively infrequent in MPM, and most
patients are treated in a palliative setting thus not under-
going surgical treatment. Very long survival may occa-
sionally occur, which could theoretically be the occurrence
of a pCR even in such a patient treated with palliative
intent. pCRs have not frequently been described in litera-
ture and is most likely a quite rare phenomenon. It is
interesting that such a dramatic response is possible, as
demonstrated by the case from our institution and in the
cases reported by Astoul et al., by Shin et al., and by Krug
et al.,10–12 which were all pCR defined by thorough exam-
ination of the whole surgical specimen taken out by pleu-
rectomy, without the finding of any malignant cells, which
makes it a fact of very high evidence. In contrast, the pCR
in the cases described by Boutin et al.8 and by Astoul et
al.7 pCR was defined by multiple biopsies without surgical
removal of the pleura. Although the latter naturally leads
to a higher level of evidence compared with evaluation by
CT only, it is still possible that there remained unbiopsied
areas, which still harbored malignant cells, even though
tumor tissue could not be discovered macroscopically
during thoracoscopy or thoracotomy. To define pCR as
precise as possible, the optimal method is thorough exam-
ination of the whole resected pleura, and to our best
knowledge, pCR defined this way have only been observed
previously in five cases10–12 and additively in the cases
from our institution.
It is interesting that this is a phenomenon that, however
rare, does exist, and it indicates that there may be variants of
this often rather chemoresistant tumor that are more respon-
sive than others. It is also interesting that among all cases of
pCR identified in this review, the histologic subtype has
either been epithelial or the subtype was not available in the
reports. So far, no cases of pCR in MPM of the sarcomatous
or the biphasic subtype have been described. The epithelial
subtype is by far the most common, which might to some
extent explain this, but another possible explanation could be
that the other subtypes are less responsive to the chemother-
apies available today.
Another interesting factor is the pretreatment stage
of disease in patients obtaining a pCR. Among the 14
patients described in the reports identified in this review 10
had stage I disease, a single patient had stage II disease,
whereas for the remaining three patients pretreatment stage
was not available in the reports. Thus, until now no cases
of pCR have been described in patients with pretreatment
stage II. The two patients observed with a pCR in our
own institution both had stage III disease before treatment,
which suggests it may be possible to obtain a pCR and the
chance of long-term survival even in patients diagnosed at
more advanced stages. It is reasonable to believe that the
occurrence of pCR would result in cure and thereby longer
survival. This was unfortunately and unexpectedly not the
case in one of the cases from our institution and neither in the
cases reported by Shin et al. However, as it is a matter of a
very limited number of patients, it is impossible to draw any
conclusions from this, and probably if a larger number of
pCRs could be seen one would also see an effect on long time
survival, as this is the case in other tumor types.
The fact that pCR can be observed and have been
observed even at advanced stages supports the use of neoad-
juvant chemotherapy. Even though pCR is very rare, the
occurrence shows that radical responses to chemotherapy is
possible, which makes it reasonable that believe that neoad-
juvant chemotherapy can lead to if not pCR then at least to an
extensive tumor burden reduction.
Further evaluation of predictive markers for mesothe-
lioma treatment is important to identify responsive patients
and could in the future lead to a customized treatment with
selection of the right treatment for the right patient.
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